GuCS

Latest GuCS News

First-Line Combo for Cisplatin-Ineligible Bladder Cancer Just Misses Positive Result

SAN FRANCISCO -- Almost half of patients with untreated cisplatin-ineligible advanced urothelial

Derick Alison Derick Alison

More Evidence That ARSIs for Prostate Cancer Differ in Cognitive Effects

SAN FRANCISCO -- Two widely used androgen receptor signaling inhibitors (ARSIs) had

Derick Alison Derick Alison

A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma

SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) boosted overall survival

Derick Alison Derick Alison

Another Prostate Cancer Screening Candidate Outperforms Standard PSA Testing

SAN FRANCISCO -- A multiparametric blood test for prostate cancer showed potential

Derick Alison Derick Alison

Adjuvant Pembrolizumab Boosts DFS in High-Risk Muscle Invasive Urothelial Cancer

SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) more than doubled

Derick Alison Derick Alison

Cabozantinib Plus Atezolizumab Delays Progression in mCRPC

SAN FRANCISCO -- In patients with metastatic castration-resistant prostate cancer (mCRPC) whose

Derick Alison Derick Alison

Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone

SAN FRANCISCO -- Combining a PARP inhibitor with an androgen receptor pathway

Derick Alison Derick Alison

Study Supports High-Dose RT, Long-Term ADT as Standard for High-Risk Prostate Cancer

SAN FRANCISCO -- Men with high-risk localized prostate cancer lived significantly longer

Derick Alison Derick Alison
adbanner